Page 92 - Sohini Das

Covishield to cost Rs 200/dose for first 100 mn doses to govt: Serum CEO

MRP for private market Rs 1,000/ dose; current licence does not allow export or sale in private market

Serum, Bharat Biotech vaccines get restricted use approval from DCGI

While the Oxford-AstraZeneca vaccine made by Serum Institute here has 70.42% efficacy, Bharat Biotech's still does not have efficacy data as trials are underway in India

Covishield moves closer to roll-out; SII gets in-principle nod from panel

India would need 30 million doses in the first phase when it vaccinates the essential services workers including health care professionals, municipal and police staff, etc

Serum Institute gets SEC thumbs up; Bharat Biotech proposal being discussed

US giant Pfizer did not come to present its case on Friday before the Subject Expert Committee

Serum Institute to seek nod for two full-dose regimen of Covishield

Suresh Jadhav, executive director of the Pune-based firm, said on Friday Serum was seeking approval from the Drug Controller General of India (DCGI) for the two-full dose regimen

State governments may use bank guarantees to buy Covid-19 vaccines

Advice comes from Centre; some states begin talks with pharma firms

Vial, syringe makers push the pedal as Covid-19 vaccine roll-out nears

Most firms plan to increase capacity to meet fresh orders

Covaxin's phase 1 trial data shows robust response: Bharat Biotech

Bharat Biotech had recently sought an accelerated approval from the regulator based on phase 1 and phase 2 studies

Govt in talks with Moderna for vaccine, yet to receive cold chain plan

Moderna's vaccine can be stored at normal fridge temperatures of 2 to 8 degrees Celsius for 30 days and it can be stored up to six months at minus 20 degree Celsius, according to reports

Pfizer may price Covid-19 vaccine lower in India than in UK and US

Cold chain of agriculture research body may come in handy

Serum likely to submit final Covid-19 vaccine trial data in 10 days

If the data is found satisfactory, an approval for Covishield, Oxford-AstraZeneca's vaccine candidate, can come in by the first week of January

Centre may not procure Pfizer-BioNTech Covid vaccine over high cost

At $37 per dose, the Pfizer vaccine is much more expensive compared to $3 per dose for the Covishield

Shelf life of vaccines likely to be more than 3 months, unlike drugs

They have the stability data for these investigational products, said a source

Recruited 8,000 volunteers already for phase 3 trials: Bharat Biotech head

The company says they are '200% transparent' about serious adverse events with regulator

ZyCoV-D shot can remain stable at room temperature: Zydus Cadila chairman

The company plans to apply for approval once it finishes phase 3 trials

Cipla settles blood cancer drug litigation with Bristol Myers in US

As it takes away the legal overhang, Cipla can launch the drug once its ANDA is approved

Gennova mRNA vaccine stable above sub-zero temperatures unlike global peers

The messenger RNA vaccine candidate contains a short, synthetic version encoding the spike protein (antigen) of the novel coronavirus Sars-CoV-2

Pune's Gennova gets nod for clinical trials of India's first mRNA vaccine

DCGI granted conditional approval for phase 1 and 2 clinical trials of Gennova's mRNA based Covid-19 vaccine candidate

Review panel asks vaccine makers to submit more data to get authorisation

Experts ask Bharat Biotech for phase 3 data, Serum's UK approval status

Expert panel set to review Pfizer-BioNTech, SII vaccine applications today

ICMR Director General Balram Bhargava said that in the case of temporary licensure or emergency use, the regulator had to be satisfied with the risk-benefit ratio.